OncoMatch/Clinical Trials/NCT07032285
Cirtuvivint in Selected Advanced Soft-Tissue Sarcomas
Is NCT07032285 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies Cirtuvivint for soft tissue sarcoma (sts).
Treatment: Cirtuvivint — The study is a Phase 2 clinical trial of the drug cirtuvivint as a second-line treatment for advanced soft tissue sarcomas. The study is being conducted in Spain and is expected to enroll approximately 25 patients in total. The primary objective of this Phase 2 study is to evaluate the efficacy of treatment with cirtuvivint. Cirtuvivint is an anti-cancer medication developed by the U.S. company Biosplice Therapeutics, Inc. This drug is an inhibitor of the enzymes CLK1-4 and DYRK1-4 (molecules involved in the cell cycle) and is administered as oral tablets. This product is still under investigation and has not yet been approved in Europe.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Sarcoma
Performance status
ECOG 0–1(Restricted strenuous activity)
Demographics
Prior therapy
Must have received: anthracycline
Patients should have received at least anthracyclines previously unless not indicated (SFT)
Cannot have received: CLK inhibitor
Previous treatment with CLK inhibitors
Cannot have received: other anti-cancer therapy or investigational product
Patients who have received any other anti-cancer therapy or investigational product in the last 28 days prior to enrollment
Lab requirements
Blood counts
Absolute neutrophil count ≥1,500/mm³; Platelet count ≥100,000/mm³
Kidney function
Creatinine ≤1.5 mg/dL
Liver function
AST and ALT ≤2.5 times upper limit of normal; Bilirubin ≤1.5 mg/dL
Cardiac function
Left ventricular ejection fraction ≥50% by echocardiogram or MUGA scan
Adequate hepatic, renal, cardiac, and hematologic function. Laboratory tests as follows: Absolute neutrophil count ≥1,500/mm³; Platelet count ≥100,000/mm³; Bilirubin ≤1.5 mg/dL; AST and ALT ≤2.5 times upper limit of normal; Creatinine ≤1.5 mg/dL. Left ventricular ejection fraction ≥50% by echocardiogram or MUGA scan.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT07032285 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior CLK inhibitor, other anti-cancer therapy or investigational product disqualifies patients from enrollment.
Is there an age limit?
Yes. Patients must be 70 years or younger and at least 16 years old.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages